Citations

Clear

4847 citation(s) found for "Yu, Eric".

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Azad, Nilofer, Chen, Yi‐Jen , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Kirilcuk, Natalie, Krishnamurthi, Smitha , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Parikh, Aparna, Patel, Hitendra , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Tavakkoli, Anna , Willett, Christopher G. , Gregory, Kristina M., Gurski, Lisa A., Meyerhardt, Jeffrey A , Venook, Alan P. , Ciombor, Kristen K. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Jeck, William R. , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 14, 2022 | Volume: 20 | Issue: 10 | Pages: 1139-1167

10.6004/jnccn.2022.0051 | PMID 36240850 Get It

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a “watch-and-wait” nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org , covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
Effect of endoscopic sleeve gastroplasty on gastric emptying, motility and hormones: a comparative prospective study
Rizk, Monika, Gomez-Villa, Jacky, Edwards, Phillip K , Jaruvongvanich, Veeravich , Acosta, Andrés , Lake, David S. , Fidler, Jeff L. , Bharucha, Adil E. , Camilleri, Michael , Vargas, Eric J , Acosta, Andres , Lake, David, Fidler, Jeff, Bharucha, A E , Camilleri, M , Abu Dayyeh, Barham K , Vargas, Eric J. , Storm, Andrew C. , Fidler, Jeff L. , Dayyeh, Barham K. Abu

Mayo Clinic

Gut | October 14, 2022 | Volume: 72 | Issue: 6 | Pages: 1073-1080

10.1136/gutjnl-2022-327816 | PMID 36241388 Get It

Objective Endoscopic sleeve gastroplasty (ESG) has gained global adoption but our understanding of its mechanism(s) of action and durability of efficacy is limited. We sought to determine changes in gastric emptying (GE), gastric motility (GM), hormones and eating behaviours after ESG. Design A priori-designed single-centre substudy of a large US randomised clinical trial, adults with obesity were randomised to ESG or lifestyle interventions (LS) alone. We measured GE, hormones and weight loss and assessed eating behaviours. In a subset of ESG patients, we assessed GM. The primary outcome was the change in T1/2 (min) at 3 months, and secondary outcomes were changes in weight, GE, GM, hormones and eating behaviours. We used t-test analyses and regression to determine the association between GE and weight loss. Results 36 (ESG=18; LS=18) participated in this substudy. Baseline characteristics were similar between the two groups. At 3 months, T1/2 was delayed in the ESG group (n=17) compared with the LS group (n=17) (152.3±47.3 vs 89.1±27.9; p<0.001). At 12 months, T1/2 remained delayed in the ESG group (n=16) vs control group (n=14) (137±37.4 vs 90.1±23.4; p<0.001). Greater delays in GE at 3 months were associated with greater weight loss. GM was preserved and fasting ghrelin, glucagon-like peptide 1 and polypeptide YY significantly increased 18 months after ESG. Conclusion ESG promotes weight loss through several key mechanistic pathways involving GE and hormones while preserving GM. These findings further support clinical adoption of this technique for the management of obesity. Trial registration number NCT03406975.
Leveraging machine learning to ascertain the implications of preoperative body mass index on surgical outcomes for 282 patients with preoperative obesity and lumbar spondylolisthesis in the Quality Outcomes Database
Agarwal, Nitin , Chan, Andrew K. , Shabani, Saman , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Haid, Regis W., Chou, Dean , Mummaneni, Praveen V. , Aabedi, Alexander A. , Letchuman, Vijay

Mayo Clinic

Journal of Neurosurgery: Spine | October 14, 2022 | Volume: 38 | Issue: 2 | Pages: 182-191

10.3171/2022.8.spine22365 | PMID 36208428 Get It

OBJECTIVE Prior studies have revealed that a body mass index (BMI) ≥ 30 is associated with worse outcomes following surgical intervention in grade 1 lumbar spondylolisthesis. Using a machine learning approach, this study aimed to leverage the prospective Quality Outcomes Database (QOD) to identify a BMI threshold for patients undergoing surgical intervention for grade 1 lumbar spondylolisthesis and thus reliably identify optimal surgical candidates among obese patients. METHODS Patients with grade 1 lumbar spondylolisthesis and preoperative BMI ≥ 30 from the prospectively collected QOD lumbar spondylolisthesis module were included in this study. A 12-month composite outcome was generated by performing principal components analysis and k-means clustering on four validated measures of surgical outcomes in patients with spondylolisthesis. Random forests were generated to determine the most important preoperative patient characteristics in predicting the composite outcome. Recursive partitioning was used to extract a BMI threshold associated with optimal outcomes. RESULTS The average BMI was 35.7, with 282 (46.4%) of the 608 patients from the QOD data set having a BMI ≥ 30. Principal components analysis revealed that the first principal component accounted for 99.2% of the variance in the four outcome measures. Two clusters were identified corresponding to patients with suboptimal outcomes (severe back pain, increased disability, impaired quality of life, and low satisfaction) and to those with optimal outcomes. Recursive partitioning established a BMI threshold of 37.5 after pruning via cross-validation. CONCLUSIONS In this multicenter study, the authors found that a BMI ≤ 37.5 was associated with improved patient outcomes following surgical intervention. These findings may help augment predictive analytics to deliver precision medicine and improve prehabilitation strategies.
Inspiratory and leg muscle blood flows during inspiratory muscle metaboreflex activation in heart failure with preserved ejection fraction
Hammer, Shane M. , Bruhn, Eric J., Bissen, Thomas G. , Muer, Jessica, Villarraga, Nicolas , Olson, Thomas P. , Smith, Joshua R. , Muer, Jessica D, Smith, Joshua R , Borlaug, Barry A.

Mayo Clinic

Journal of Applied Physiology | October 13, 2022 | Volume: 133 | Issue: 5 | Pages: 1202-1211

10.1152/japplphysiol.00141.2022 | PMID 36227167 Get It

Respiratory muscle dysfunction is thought to contribute to exercise intolerance in heart failure with preserved ejection fraction (HFpEF); however, the underlying mechanisms are unknown. In the present study, patients with HFpEF had greater increases in leg muscle vascular resistance index and greater decreases in leg muscle blood flow index compared with controls during inspiratory resistive breathing (to activate the metaboreflex). Furthermore, respiratory muscle blood flow index responses normalized to pressure generation during inspiratory resistive breathing were exaggerated in HFpEF compared with controls.
Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment
Durot, Éric , Tomowiak, Cécile , Toussaint, Elise , Morel, Pierre , Talaulikar, Dipti , Kapoor, Prashant , Castillo, Jorge J. , Delmer, Alain , Talaulikar, Dipti , Tomowiak, Cécile , Castillo, Jorge J , Delmer, Alain Jacques , Durot, Eric

Mayo Clinic

Hemato | October 12, 2022 | Volume: 3 | Issue: 4 | Pages: 650-662

10.3390/hemato3040044 Get It

Histological transformation (HT) to an aggressive lymphoma results from a rare evolution of Waldenström macroglobulinemia (WM). A higher incidence of transformation events has been reported in MYD88 wild-type WM patients. HT in WM can be histologically heterogeneous, although the diffuse large B-cell lymphoma of activated B-cell subtype is the predominant pathologic entity. The pathophysiology of HT is largely unknown. The clinical suspicion of HT is based on physical deterioration and the rapid enlargement of the lymph nodes in WM patients. Most transformed WM patients present with elevated serum lactate dehydrogenase (LDH) and extranodal disease. A histologic confirmation regarding the transformation to a higher-grade lymphoma is mandatory for the diagnosis of HT, and the choice of the biopsy site may be dictated by the findings of the 18fluorodeoxyglucose-positron emission tomography/computed tomography. The prognosis of HT in WM is unfavorable, with a significantly inferior outcome compared to WM patients without HT. A validated prognostic score based on 3 adverse risk factors (elevated LDH, platelet count < 100 × 109/L and any previous treatment for WM) stratifies patients into 3 risk groups. The most common initial treatment used is a chemo-immunotherapy (CIT), such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). The response duration is short and central nervous system relapses are frequent. Whether autologous stem cell transplantation could benefit fit patients responding to CIT remains to be studied.
Adenoid cystic carcinoma of the head and neck: Patterns of recurrence and implications for intensity‐modulated radiotherapy
Gao, Robert W. , Routman, David M. , Harmsen, William S. , Ebrahimi, Sasha , Foote, Robert L. , Neben-Wittich, M.A. , McGee, L.A. , Patel, Samir H. , Moore, Eric J. , Tasche, Kendall K. , Price, Katharine A., Gamez, Mauricio E. , Neben-Wittich, Michelle, McGee, Lisa A, Moore, Eric J , Choby, Garret , Lester, Scott C. , Routman, David M , Daniel, J. , Choby, Garret

Mayo Clinic

Head & Neck | October 12, 2022 | Volume: 45 | Issue: 1 | Pages: 187-196

10.1002/hed.27223 | PMID 36222355 Get It

AbstractBackgroundWe seek to inform radiotherapy (RT) delivery for adenoid cystic carcinoma of the head and neck (ACC) by evaluating RT techniques and recurrence patterns.MethodsWe identified patients with ACC treated with curative‐intent RT from 2005 to 2021. Imaging was reviewed to determine local recurrence (LR).ResultsNinety‐one patients were included. The 5‐year LR risk was 12.2% (6.6–22.7). One patient each experienced a marginal and out‐of‐field recurrence. Patients receiving >60 Gy postoperatively had a 5‐year LR risk of 0% compared to 10.7% (4.2–27.2) with ≤60 Gy. Those receiving 70 and <70 Gy definitively had a 5‐year LR risk of 15.2% (2.5–91.6) and 33.3% (6.7–100.0), respectively. No patients had regional nodal failure.ConclusionsModern, conformal RT for ACC results in low rates of LR. Doses >60 and 70 Gy may improve control in the postoperative and definitive settings, respectively. Elective nodal treatment can be omitted in well‐selected patients.
Cellular Sources and Neuroprotective Roles of Interleukin-10 in the Facial Motor Nucleus after Axotomy
Runge, Elizabeth M. , Setter, Deborah O. , Iyer, Abhirami K. , Regele, Eric J. , Kennedy, Felicia M., Sanders, Virginia M., Jones, Kathryn J.

Mayo Clinic

Cells | October 9, 2022 | Volume: 11 | Issue: 19 | Pages: 3167

10.3390/cells11193167 | PMID 36231129 Get It

Facial motoneuron (FMN) survival is mediated by CD4+ T cells in an interleukin-10 (IL-10)-dependent manner after facial nerve axotomy (FNA), but CD4+ T cells themselves are not the source of this neuroprotective IL-10. The aims of this study were to (1) identify the temporal and cell-specific induction of IL-10 expression in the facial motor nucleus and (2) elucidate the neuroprotective capacity of this expression after axotomy. Immunohistochemistry revealed that FMN constitutively produced IL-10, whereas astrocytes were induced to make IL-10 after FNA. Il10 mRNA co-localized with microglia before and after axotomy, but microglial production of IL-10 protein was not detected. To determine whether any single source of IL-10 was critical for FMN survival, Cre/Lox mouse strains were utilized to selectively knock out IL-10 in neurons, astrocytes, and microglia. In agreement with the localization data reflecting concerted IL-10 production by multiple cell types, no single cellular source of IL-10 alone could provide neuroprotection after FNA. These findings suggest that coordinated neuronal and astrocytic IL-10 production is necessary for FMN survival and has roles in neuronal homeostasis, as well as neuroprotective trophism after axotomy.
Demographic Representation Among Speakers and Program Committee Members at the IDWeek Conference, 2013–2021
Marcelin, Jasmine R , Khazanchi, Rohan , Lyden, Elizabeth, Florez, Narjust , Kullar, Ravina , Ristagno, Elizabeth H. , group, the Introduction of Speakers at IDWeek Events Observing for Unconscious Bias over Time (INSIDE-OUT) study, Rajapakse, Nipunie , Patel, Megha, Miller, Amy M. , Oeltjen, Erin N, Semaj, Sophie, Sramek, Kyle T, Lindeman, Christopher J, Daubach, Eric C., Akinmoladun, Oladapo O, Wurtz, Paul J, Marcelin, Jasmine , Lyden, Elizabeth , Cawcutt, Kelly , Ha, David R , Florez, Narjust , group, the Introduction of Speakers at IDWeek Events Observing for Unconscious Bias over Time (INSIDE-OUT) study, Patel, Megha, Akinmoladun, Oladapo O., Yang, Yuhong

Mayo Clinic

Clinical Infectious Diseases | October 6, 2022 | Volume: 76 | Issue: 5 | Pages: 897-904

10.1093/cid/ciac816 | PMID 36208201 Get It

AbstractBackgroundIn 2016, the IDWeek program committee was charged with ensuring gender equity in speaker sessions. Whether this charge also resulted in more opportunities for historically underrepresented speakers is unknown.MethodsWe conducted a retrospective analysis of trends in the demographic composition of IDWeek speakers and program committee members between 2013 and 2021. We used descriptive statistics to summarize data, χ2 tests to compare speaker demographics between 2013–2016 (before 2016) and 2017–2021 (after 2016), and Cochran–Armitage tests for trend. Each speaker slot was considered an independent event.ResultsA total of 5482 speaker slots were filled by 3389 individuals from 2013 to 2021. There was a linear increase in female speakers from 38.6% in 2013 to 58.4% in 2021 (P &lt; .001). The proportion of white speakers decreased overall from 84.9% in 2013 to 63.5% in 2021. Compared with white speakers, more slots were filled by Asian speakers after 2016 versus before 2016 (20.1% vs 14.8%, respectively; P &lt; .001). Program committee members from 2013–2021 were &gt;80% non-Hispanic white; &lt;5% of committee members identified as black, American Indian, Alaska Native, Native Hawaiian, Pacific Islander, or Hispanic. More program committee slots were filled by women after 2016 than before 2016 (52.7% vs 33.9%; P = .004).ConclusionsIntentional consideration of gender equity by the program committee was associated with equitable gender representation of invited speakers at IDWeek after 2016. Gradually, the proportions of IDWeek speakers from historically excluded racial/ethnic approached their respective proportions in the IDSA membership. White speakers remained overrepresented relative to membership proportions until 2021, and gaps in program committee racial/ethnic demographic representation highlights opportunities for continued inclusion, diversity, access, and equity at IDWeek.
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study
Deng, Yihong , Wallach, Joshua D. , Dhruva, Sanket S. , Quinto, Kenneth , Gandotra, Charu , Crown, William H. , Lyon, Timothy D. , Shah, Nilay D. , McCoy, Rozalina Grubina , Wallach, Joshua D , Lyon, Timothy D , Deng, Yihong , Polley, Eric C. , Herrin, Jeph , Noseworthy, Peter A. , Yao, Xiaoxi , Ross, Joseph S. , McCoy, Rozalina G.

Mayo Clinic

BMJ | October 3, 2022 | Volume: 379 | Issue: No issue available | Pages: e070717

10.1136/bmj-2022-070717 | PMID 36191949 Get It

Abstract Objective To emulate the GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) trial using real world data before its publication. GRADE directly compared second line glucose lowering drugs for their ability to lower glycated hemoglobin A 1c (HbA 1c ). Design Observational study. Setting OptumLabs® Data Warehouse (OLDW), a nationwide claims database in the US, 25 January 2010 to 30 June 2019. Participants Adults with type 2 diabetes and HbA 1c 6.8-8.5% while using metformin monotherapy, identified according to the GRADE trial specifications, who also used glimepiride, liraglutide, sitagliptin, or insulin glargine. Main outcome measures The primary outcome was time to HbA 1c ≥7.0%. Secondary outcomes were time to HbA 1c >7.5%, incident microvascular complications, incident macrovascular complications, adverse events, all cause hospital admissions, and all cause mortality. Propensity scores were estimated using the gradient boosting machine method, and inverse propensity score weighting was used to emulate randomization of the treatment groups, which were then compared using Cox proportional hazards regression. Results 8252 people were identified (19.7% of adults starting the study drugs in OLDW) who met eligibility criteria for the GRADE trial (glimepiride arm=4318, liraglutide arm=690, sitagliptin arm=2993, glargine arm=251). The glargine arm was excluded from analyses owing to small sample size. Median times to HbA 1c ≥7.0% were 442 days (95% confidence interval 394 to 480 days) for glimepiride, 764 (741 to not calculable) days for liraglutide, and 427 (380 to 483) days for sitagliptin. Liraglutide was associated with lower risk of reaching HbA 1c ≥7.0% compared with glimepiride (hazard ratio 0.57, 95% confidence interval 0.43 to 0.75) and sitagliptin (0.55, 0.41 to 0.73). Results were consistent for the secondary outcome of time to HbA 1c >7.5%. No significant differences were observed among treatment groups for the remaining secondary outcomes. Conclusions In this emulation of the GRADE trial, liraglutide was statistically significantly more effective at maintaining glycemic control than glimepiride or sitagliptin when added to metformin monotherapy. Generating timely evidence on medical treatments using real world data as a complement to prospective trials is of value.